Real‐World Assessment of rVIII‐SingleChain for Prophylactic Treatment in People With Severe Hemophilia A in High‐Resource Settings
Haemophilia · 2026-11 · 32 (6) · 1421-1428
DOI: 10.1111/hae.70349 ↗Abstract
ABSTRACT Introduction rVIII‐SingleChain has been approved and reimbursed in Taiwan since September 2020 as prophylaxis for severe hemophilia A. Aim This study compared real‐world outcomes of prophylactic treatment with rVIII‐SingleChain versus other long‐acting FVIII products in people with severe hemophilia A (PwSHA) in Taiwan. Methods A retrospective de‐identified patient chart‐review‐based study was conducted in three hemophilia treatment centers in Taiwan (September 2019‐August 2021). Data of PwSHA who used rVIII‐SingleChain or other long‐acting FVIII products for prophylaxis (for ≥12 weeks following 1 September 2020) were included. Current treatment regimen, factor consumption, and bleeding events (annualized bleeding rate [ABR], annualized joint bleeding rate [AjBR], annualized spontaneous bleeding rate [AsBR]) data were collected from medical records. Results Overall, 39 patients were enrolled (rVIII‐SingleChain: n = 14; other long‐acting FVIII products: n = 25). Median (IQR) factor VIII consumption (IU/kg/week) was: 97.7 (92.3–103.2) for rVIII‐SingleChain and 81.4 (71.0–90.3) for other long‐acting FVIII products; 11/14 patients (78.6%) and 23/25 patients (92.0%), respectively, were dosed ≤2 times/week. Median (IQR) bleeding rates of rVIII‐SingleChain versus other long‐acting FVIII products were: ABR, 0.0 (0.0–9.8) vs 2.0 (0.0–5.0); AsBR, 0.0 (0.0–3.3) vs 1.0 (0.0–4.0); and AjBR, 0.0 (0.0–7.6) vs 0.0 (0.0–5.0). Half‐life (hr) was comparable between O and non‐O blood type patients for rVIII‐SingleChain (mean ± SD: 15.3 ± 6.3 vs 17.8 ± 2.2; p = 0.1243) and rurioctocog alfa pegol (15.3 ± NA vs 17.6 ± 2.8; p = 0.3711); but significantly higher in non‐O than O blood type for efmoroctocog alfa (20.6 ± 3.6 vs 14.6 ± 3.9; p = 0.0292). Conclusion rVIII‐SingleChain prophylactic treatment demonstrated effective bleeding control in PwSHA in Taiwan, with low dosing frequency (≤2 times/week) in most PwSHA.
EUVIMED